Research map: GLP-1RA PHARMACOKINETICS AND CLINICAL EFFECTS: FOCUS ON CARDIAC, VASCULAR, AND GLOMERULAR STRUCTURES

Back to the article

Papers in this map

  1. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes · Steven P. Marso · 2016 · 7637 citations · Cited by this paper
  2. Tirabrutinib–anthracycline interactions in the brain tumor microenvironment: a focus on metabolic inactivation and resistance · 2025 · Related
  3. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes · Steven P. Marso · 2016 · 6910 citations · Cited by this paper
  4. Microbiome-driven PKs: redefining drug metabolism beyond host enzymes · 2026 · Related
  5. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial · Hertzel C. Gerstein · 2019 · 3179 citations · Cited by this paper
  6. Combined oral contraceptives and pharmacokinetic drug interactions: impact on efficacy and safety · 2026 · Related
  7. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes · A. Michael Lincoff · 2023 · 3058 citations · Cited by this paper
  8. Predicting the potential for organic cation transporter 1-mediated drug–drug interactions with fenoterol by amitriptyline, fluoxetine, selegiline, metformin, and verapamil · 2026 · Related
  9. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes · Rury R. Holman · 2017 · 2197 citations · Cited by this paper
  10. Pharmacokinetics and safety of the combination of KL130008 and methotrexate in rheumatoid arthritis patients: a multicenter, open-label phase Ib trial · 2025 · Related
  11. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes · Juan P. Frías · 2021 · 2036 citations · Cited by this paper
  12. Evaluation of the drug-drug interaction between low-dose methotrexate and short-term use of non-steroidal anti-inflammatory drugs · 2025 · Related
  13. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  14. Modifying Hy’s Law and eDISH for the modern idiosyncratic DILI era · 2025 · Related
  15. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity · Mikhail Kosiborod · 2023 · 1621 citations · Cited by this paper
  16. Exploring the influence of sex on idiosyncratic DILI: impact on risk assessment · 2026 · Related
  17. Liraglutide and Renal Outcomes in Type 2 Diabetes · Johannes F.E. Mann · 2017 · 1269 citations · Cited by this paper
  18. Complex in vitro model developers’ perspective on advanced hepatic in vitro culture methods for predictive drug safety · 2026 · Related
  19. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial · Ania M. Jastreboff · 2023 · 1110 citations · Cited by this paper
  20. An update on the pharmacokinetic and pharmacodynamic interactions between antidepressants and antiseizure medications · 2026 · Related
  21. GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody · Charles Pyke · 2014 · 870 citations · Cited by this paper
  22. GIP and GLP‐1, the two incretin hormones: Similarities and differences · Yutaka Seino · 2010 · 745 citations · Cited by this paper
  23. A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity · Aaron S. Kelly · 2020 · 713 citations · Cited by this paper
  24. Once-Weekly Semaglutide in Adolescents with Obesity · Daniel Weghuber · 2022 · 704 citations · Cited by this paper
  25. The Cardiovascular Biology of Glucagon-like Peptide-1 · Daniel J. Drucker · 2016 · 660 citations · Cited by this paper
  26. Strategic Approaches to Optimizing Peptide ADME Properties · Li Di · 2014 · 659 citations · Cited by this paper
  27. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial · Hertzel C. Gerstein · 2019 · 645 citations · Cited by this paper
  28. Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury · Amal Bose · 2005 · 636 citations · Cited by this paper
  29. GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice · Mohammad Hossein Noyan-Ashraf · 2009 · 579 citations · Cited by this paper
  30. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist · Stephen Timothy Buckley · 2018 · 540 citations · Cited by this paper
  31. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways · Günaj Rakipovski · 2018 · 520 citations · Cited by this paper
  32. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA · Julio Rosenstock · 2023 · 409 citations · Cited by this paper
  33. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes · Darren K. McGuire · 2025 · 383 citations · Cited by this paper
  34. Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration · Wolfgang F Richter · 2012 · 372 citations · Cited by this paper
  35. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials · Sunil V. Badve · 2024 · 332 citations · Cited by this paper
  36. GLP-1 Receptor Expression Within the Human Heart · Laurie L. Baggio · 2018 · 317 citations · Cited by this paper
  37. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia–reperfusion injury in rat heart · David Peick Sonne · 2007 · 295 citations · Cited by this paper
  38. Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase · Monika Malm-Erjefält · 2010 · 201 citations · Cited by this paper
  39. Effect of renal impairment on the pharmacokinetics of exenatide · Helle Linnebjerg · 2007 · 200 citations · Cited by this paper

Source: OpenAlex (CC0)